http://www.wikiweed.com/index.php?action=history&feed=atom&title=S-444%2C823S-444,823 - Revision history2026-04-28T14:52:41ZRevision history for this page on the wikiMediaWiki 1.24.1http://www.wikiweed.com/index.php?title=S-444,823&diff=1365&oldid=prevAdm1n at 11:06, 15 February 20152015-02-15T11:06:59Z<p></p>
<table class='diff diff-contentalign-left'>
<col class='diff-marker' />
<col class='diff-content' />
<col class='diff-marker' />
<col class='diff-content' />
<tr style='vertical-align: top;'>
<td colspan='2' style="background-color: white; color:black; text-align: center;">← Older revision</td>
<td colspan='2' style="background-color: white; color:black; text-align: center;">Revision as of 11:06, 15 February 2015</td>
</tr><tr><td colspan="2" class="diff-lineno">Line 1:</td>
<td colspan="2" class="diff-lineno">Line 1:</td></tr>
<tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>S-444,823 is a drug developed by Shionogi which is a [[cannabinoid]] agonist. It was developed as an antipruritic, and has moderate selectivity for the [[CB2]] subtype, having a CB2 affinity of 18nM, and 32x selectivity over the [[CB1]] receptor. In animal studies it showed analgesic effects and strongly reduced itching responses, but without producing side effects such as sedation and catalepsy that are seen with centrally acting CB1 agonists.</div></td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">'''</ins>S-444,823<ins class="diffchange diffchange-inline">''' </ins>is a drug developed by Shionogi which is a [[cannabinoid]] agonist. It was developed as an antipruritic, and has moderate selectivity for the [[CB2]] subtype, having a CB2 affinity of 18nM, and 32x selectivity over the [[CB1]] receptor. In animal studies it showed analgesic effects and strongly reduced itching responses, but without producing side effects such as sedation and catalepsy that are seen with centrally acting CB1 agonists.</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td></tr>
</table>Adm1nhttp://www.wikiweed.com/index.php?title=S-444,823&diff=1364&oldid=prevAdm1n: Created page with "S-444,823 is a drug developed by Shionogi which is a cannabinoid agonist. It was developed as an antipruritic, and has moderate selectivity for the CB2 subtype, having..."2015-02-15T11:06:46Z<p>Created page with "S-444,823 is a drug developed by Shionogi which is a <a href="/Cannabinoid" title="Cannabinoid">cannabinoid</a> agonist. It was developed as an antipruritic, and has moderate selectivity for the <a href="/CB2" title="CB2">CB2</a> subtype, having..."</p>
<p><b>New page</b></p><div>S-444,823 is a drug developed by Shionogi which is a [[cannabinoid]] agonist. It was developed as an antipruritic, and has moderate selectivity for the [[CB2]] subtype, having a CB2 affinity of 18nM, and 32x selectivity over the [[CB1]] receptor. In animal studies it showed analgesic effects and strongly reduced itching responses, but without producing side effects such as sedation and catalepsy that are seen with centrally acting CB1 agonists.<br />
<br />
<br />
== See also ==<br />
<br />
*[[JTE 7-31]]</div>Adm1n